CHARLOTTE, NC —
Bright Path Pharmaceuticals, LLC (privately held) today announced that Todd N. Smith, Chairman and CEO of Novum Pharma will join the Board. Mr. Smith has twenty five years of pharmaceutical, medical device and biotechnology general management experience and a long track record of building companies and achieving commercial and business development excellence. Mr. Smith served as Executive Vice President and Chief Commercial Officer at Horizon Pharma where he was instrumental in building and executing the commercial model and Business Development strategy that increased Horizon’s market cap from $200M to $5B. Mr. Smith has led and participated in 25+ product launches including several billion dollar brands and product portfolios, and has built high-performing commercial teams at top companies including Bayer, Abbott, Horizon Pharma, Agouron and Fenwal Inc.
Mr. Quinones elated stated, “We are determined to recruit the best talent to our Board and Todd possesses the type of leadership we need.” Mr. Allen affirmed, “Todd is fine pharma executive, the best, and his skills in the pharma business are only exceeded by his personal character and integrity.”
About Bright Path Pharmaceuticals, LLC
Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathrx.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.